The unique code, 0433U, was issued to Oxford BioDynamics for the 94% accurate EpiSwitch Prostate Screening (PSE) test. The code was published on 29 September and payors will be able to bill for the test using the code from
The new CPT code provides a standardized billing mechanism for the PSE Test across all US healthcare providers, ensuring accurate reimbursement. This development ensures patients have greater access to the test by simplifying the reimbursement process and eliminating administrative complexity.
The PSE Test was launched on
Despite the AMA's commitment to issuing CPT codes in a timely manner it is often a difficult task for companies to navigate the process and it can take up to 2 years.
OBD's management believes that the speed of issuance of the CPT code demonstrates that the payor groups recognize how important PSE is for screening, not only for the patients, but also for the savings to the medical industry.
'A unique code is critical to the reimbursement process,' said
As with the Company's previous test, the checkpoint inhibitor response test (CiRT), launched in early 2022 for prediction of response to checkpoint inhibitor therapy in cancer, a miscellaneous code for high complexity molecular testing will be used for reimbursement in the fourth quarter of 2023. A CPT PLA code is unique to the test, the lab and the manufacturer. The full (long) description for PSE is 'Oncology (prostate), five DNA regulatory markers by quantitative PCR, whole blood, algorithm, including Prostate-Specific Antigen, reported as likelihood of cancer'.
Contact:
Tel: +44 (0)1865 518910
Email: OxfordBioDynamics@instinctif.com
About
Its flagship products are the EpiSwitch CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch PSE (EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in
In
The Company's product portfolio is based on a proprietary 3D genomic biomarker platform, EpiSwitch, which can build molecular diagnostic classifiers for the prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases.
OBD is headquartered in
About EpiSwitch
The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch can be used to diagnose patients or determine how individuals might respond to a disease or treatment.
Built on over 10 years of research, EpiSwitch is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 15,000 samples in 30 disease areas, and reduced to practice.
In addition to stratifying patients with respect to anticipated clinical outcomes, EpiSwitch data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.
(C) 2023 Electronic News Publishing, source